Benign prostatic hyperplasia: Does lifestyle play a role?

Physician and Sportsmedicine

Volumn 37, Issue 4, 2009, Pages 141-146

  Barnard, R James ^a   Aronson, William J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diet; Estrogen; Exercise; Insulin; Insulin like growth factor 1; Testosterone

Indexed keywords

ESTRADIOL; INSULIN; SOMATOMEDIN C; TESTOSTERONE;

ARTICLE; CANCER CELL CULTURE; CANCER RISK; ESTRADIOL BLOOD LEVEL; EXERCISE; HIGH FIBER DIET; HUMAN; LIFESTYLE; LIFESTYLE MODIFICATION; PROSTATE; PROSTATE BIOPSY; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY;

EID: 76149118426     PISSN: 00913847     EISSN: None     Source Type: Journal    
DOI: 10.3810/psm.2009.12.1752     Document Type: Article

References (52)

1. Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008;20(suppl 3):S11-S18.
2. Blom JH, Schröder FH. Epidemiology and natural course of benign prostatic hyperplasia, [in German]. Urologe A. 1992;31(3):129-134.
3. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol. 2005;40(3):121-128.
4. Prezioso D, Denis LJ, Klocker H, et al. Estrogens and aspects of prostate disease. Int J Urol. 2007;14(1):1-16.
5. Hammarsten J, Damber JE, Karlsson M, et al. Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2009;12(2):160-165.
6. Boehm S, Nirnberger G, Ferrari P. Estrogen suppression as a pharmacotherapeutic strategy in the medical treatment of benign prostatic hyperplasia: evidence for its efficacy from studies with mepartricin. Wien Klin Wochenschr. 1998;110(23):817-823.
7. Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998;1(3):157-162.
8. Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol. 2001;39(2):151-158.
9. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta. 2006;370(1-2):89-93.
10. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 2002;168(2):599-604.
11. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol. 2007;51(1):199-203.
12. Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology. 2006;68(6):1198-1205.
13. Tymchuk CN, Barnard RJ, Ngo TH, Aronson WJ. Role of testosterone, estradiol, and insulin in diet- and exercise-induced reductions in serum-stimulated prostate cancer cell growth in vitro. Nutr Cancer. 2002;42(1): 112-116.
14. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab. 1988;67(3):460-464.
15. Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab. 1991;73(2):401-407.
16. Grant ES, Ross MB, Ballard S, Naylor A, Habib FK. The insulin-like growth factor type I receptor stimulates growth and suppresses apoptosis in prostatic stromal cells. J Clin Endocrinol Metab. 1998;83(9):3252-3257.
17. Chokkalingam AP, Gao YT, Deng J, et al. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate. 2002;52(2):98-105.
18. Neuhouser ML, Schenk J, Song YJ, et al. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate. 2008; 68(13):1477-1486.
19. Alcaraz A, Hammerer P, Tubaro A, Schröder FH, Castro R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol. 2009;55(4): 864-873.
20. Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer. 1992;70(1 suppl):291-301.
21. Hammarsten J, Högstedt B. Calculated fast-growing benign prostatic hyperplasia-a risk factor for developing clinical prostate cancer. Scand J Urol Nephrol. 2002;36(5):330-338.
22. Hammarsten J, Högstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer. 2005;41(18): 2887-2895.
23. Hammarsten J, Högstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press. 2004;13(1):47-55.
24. König JE, Senge T, Allhoff EP, König W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate. 2004;58(2):121-129.
25. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51(5): 1202-1216.
26. Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, Gentile V. Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol. 2007;52(4):964-972.
27. St Sauver JL, Jacobson DJ, McGree ME, Girman CJ, Lieber MM, Jacobsen SJ. Longitudinal association between prostatitis and development of benign prostatic hyperplasia. Urology. 2008;71(3):475-479.
28. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999;155(6):1985-1992.
29. Caruso C, Lio D, Cavallone L, Franceschi C. Aging, longevity, inflammation, and cancer. Ann N Y Acad Sci. 2004;1028:1-13.
30. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7(4):256-269.
31. Tam NN, Leav I, Ho SM. Sex hormones induce direct epithelial and inflammation-mediated oxidative/nitrosative stress that favors prostatic carcinogenesis in the noble rat. Am J Pathol. 2007;171(4):1334-1341.
32. Barnard RJ. Prevention of cancer through lifestyle changes. Evid Based Complement Alternat Med. 2004;1(3):233-239.
33. Bravi F, Bosetti C, Dal Maso L, et al. Food groups and risk of benign prostatic hyperplasia. Urology. 2006;67(1):73-79.
34. Suzuki S, Platz EA, Kawachi I, Willett WC, Giovannucci E. Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am J Clin Nutr. 2002;75(4):689-697.
35. Rohrmann S, Giovannucci E, Willett WC, Platz EA. Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. Am J Clin Nutr. 2007;85(2):523-529.
36. Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol. 2008;53(6):1228-1235.
37. Tymchuk CN, Tessler SB, Aronson WJ, Barnard RJ. Effects of diet and exercise on insulin, sex hormone-binding globulin, and prostate-specific antigen. Nutr Cancer. 1998;31(2):127-131.
38. Tymchuk CN, Barnard RJ, Heber D, Aronson WJ. Evidence of an inhibitory effect of diet and exercise on prostate cancer cell growth. J Urol. 2001;166(3):1185-1189.
39. Ngo TH, Barnard RJ, Tymchuk CN, Cohen P, Aronson WJ. Effect of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and growth of LNCaP cells in vitro (United States). Cancer Causes Control. 2002; 13(10):929-935.
40. Barnard RJ, Ngo TH, Leung PS, Aronson WJ, Golding LA. A low-fat diet and/or strenuous exercise alters the IGF axis in vivo and reduces prostate tumor cell growth in vitro. Prostate. 2003;56(3):201-206.
41. Nguyen MT, Favelyukis S, Nguyen AK, et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem. 2007;282(48):35279-35292.
42. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene. 2008;27(2):218-224.
43. Nelson EC, Evans CP, Mack PC, Devere-White RW, Lara PN Jr. Inhibition of Akt pathways in the treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2007;10(4):331-339.
44. Shida Y, Igawa T, Hakariya T, Sakai H, Kanetake H. p38MAPK activation is involved in androgen-independent proliferation of human prostate cancer cells by regulating IL-6 secretion. Biochem Biophys Res Commun. 2007;353(3):744-749.
45. Soliman S, Aronson WJ, Barnard RJ. Analyzing serum-stimulated prostate cancer cell fines after low-fat, high-fiber diet and exercise intervention. Published online ahead of print. 2009. Evid Based Complement Alternat Med.
46. Barnard RJ. Effects of life-style modification on serum lipids. Arch Intern Med. 1991;151(7):1389-1394.
47. Rosenthal MB, Barnard RJ, Rose DP, Inkeles S, Hall J, Pritikin N. Effects of a high-complex-carbohydrate, low-fat, low-cholesterol diet on levels of serum lipids and estradiol. Am J Med. 1985;78(1):23-27.
48. Barnard RJ, Kobayashi N, Aronson WJ. Effect of diet and exercise intervention on the growth of prostate epithelial cells. Prostate Cancer Prostatic Dis. 2008;11(4):362-366.
49. Aronson WJ, Glaspy JA, Reddy ST, Reese D, Heber D, Bagga D. Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology. 2001;58(2):283-288.
50. Lin DW, Neuhouser ML, Schenk JM, et al. Low-fat, low-glycemic load diet and gene expression in human prostate epithelium: a feasibility study of using cDNA microarrays to assess the response to dietary intervention in target tissues. Cancer Epidemiol Biomarkers Prev. 2007;16(10): 2150-2154.
51. Ornish D, Magbanua MJ, Weidner G, et al. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A. 2008;105(24):8369-8374.
52. Barnard RJ. Prostate cancer prevention by nutritional means to alleviate metabolic syndrome. Am J Clin Nutr. 2007;86(3):s889-s893.